 |
160 Products |  |
813 Diseases | | 160 Products |
|
1618 Trials |  |
78436 News |  |
| «12...890891892893894895896897898899900...910911» |
- |||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion, Metastases: Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 25, 2013
P2, N=72, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Enrollment change, Metastases: Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma (clinicaltrials.gov) - Mar 24, 2013
P2, N=34, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed N=116 --> 34
- | plerixafor / Generic mfg.
New P2 trial: Plerixafor for Stem Cell Mobilization in Normal Donors (clinicaltrials.gov) - Mar 24, 2013
P2, N=30, Recruiting, Sponsor: M.D. Anderson Cancer Center
- AMG 811 / Amgen
Trial completion: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis (clinicaltrials.gov) - Mar 24, 2013
P1, N=9, Completed, Sponsor: Amgen
N=116 --> 34 Recruiting --> Completed
- |||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Trial completion: Study To Assess FRacTure Healing With SclerosTin Antibody - Hip (clinicaltrials.gov) - Mar 24, 2013
P2, N=332, Completed, Sponsor: Amgen
Recruiting --> Completed Recruiting --> Completed
- Avastin (bevacizumab) / Roche
Enrollment change, Combination therapy, Metastases: HAI Abraxane With Gemcitabine and Bevacizumab (clinicaltrials.gov) - Mar 21, 2013
P1, N=80, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed N=60 --> 80
- trebananib (AMG 386) / Amgen, Avastin (bevacizumab) / Roche
Enrollment open: Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors (clinicaltrials.gov) - Mar 21, 2013
P2, N=141, Recruiting, Sponsor: National Cancer Institute (NCI)
N=60 --> 80 Suspended --> Recruiting
- |||| Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis
Enrollment open: BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) (clinicaltrials.gov) - Mar 20, 2013
P2, N=200, Recruiting, Sponsor: GlaxoSmithKline
Suspended --> Recruiting Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
New P2 trial: Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab (clinicaltrials.gov) - Mar 18, 2013
P2, N=35, Recruiting, Sponsor: Christina Wu
- |||||||||| Repatha (evolocumab) / Amgen, Astellas
New P3 trial: GLAGOV: GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound (clinicaltrials.gov) - Mar 17, 2013
P3, N=950, Recruiting, Sponsor: Amgen
- Decadron (dexamethasone) / Merck (MSD), Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment open: Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 17, 2013
P=N/A, N=20, Recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting Suspended --> Recruiting
- HEOR: Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis (clinicaltrials.gov) - Mar 14, 2013
P=N/A, N=1000, Not yet recruiting, Sponsor: Jochen Schmitt.
- ||| Vectibix (panitumumab) / Amgen
Enrollment open: Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Mar 14, 2013
P=N/A, N=740, Enrolling by invitation, Sponsor: Amgen
Suspended --> Recruiting Not yet recruiting --> Enrolling by invitation
- | Vectibix (panitumumab) / Amgen
Trial suspension: Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer (clinicaltrials.gov) - Mar 12, 2013
P2, N=134, Suspended, Sponsor: WiSP Wissenschaftlicher Service Pharma GmbH
Not yet recruiting --> Enrolling by invitation Recruiting --> Suspended
- |||| Nplate (romiplostim) / Amgen
Trial completion, Metastases: AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin (clinicaltrials.gov) - Mar 12, 2013
P1/2, N=55, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Suspended Active, not recruiting --> Completed
- Stivarga (regorafenib) / Bayer
Trial withdrawal, Metastases: Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines (clinicaltrials.gov) - Mar 11, 2013
P3, N=0, Withdrawn, Sponsor: Asan Medical Center
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Stivarga (regorafenib) / Bayer
Enrollment change, Metastases: Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines (clinicaltrials.gov) - Mar 11, 2013
P3, N=0, Withdrawn, Sponsor: Asan Medical Center
Not yet recruiting --> Withdrawn N=224 --> 0
- | vinorelbine tartrate / Generic mfg., gemcitabine / Generic mfg.
Enrollment change: Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma (clinicaltrials.gov) - Mar 11, 2013
P2, N=33, Completed, Sponsor: Children's Oncology Group
N=224 --> 0 N=26 --> 33
- |||| Imlygic (talimogene laherparepvec) / Amgen
Enrollment open: Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma (clinicaltrials.gov) - Mar 10, 2013
P1/2, N=149, Recruiting, Sponsor: Amgen
N=26 --> 33 Not yet recruiting --> Recruiting
- |||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Trial completion: Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing (clinicaltrials.gov) - Mar 10, 2013
P2, N=402, Completed, Sponsor: Amgen
Not yet recruiting --> Recruiting Recruiting --> Completed
- Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
Enrollment change: Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (clinicaltrials.gov) - Mar 8, 2013
P=N/A, N=55, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed N=40 --> 55
- ThermoDox (lyso-thermosensitive liposomal doxorubicin) / Imunon
Trial termination: Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer (clinicaltrials.gov) - Mar 7, 2013
P1, N=29, Terminated, Sponsor: Kimberly Blackwell
N=40 --> 55 Recruiting --> Terminated; Funding
- ||||| Epogen (epoetin alfa) / Amgen, Omontys (peginesatide) / Affymax
Enrollment change: DIAMOND: Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis (clinicaltrials.gov) - Mar 7, 2013
P3, N=184, Completed, Sponsor: Affymax
Recruiting --> Terminated; Funding N=240 --> 184
- ||||||| Epogen (epoetin alfa) / Amgen, Omontys (peginesatide) / Affymax
Trial completion: DIAMOND: Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis (clinicaltrials.gov) - Mar 7, 2013
P3, N=184, Completed, Sponsor: Affymax
N=240 --> 184 Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
New P2 trial: Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy (clinicaltrials.gov) - Mar 6, 2013
P2, N=110, Recruiting, Sponsor: St. Jude Children's Research Hospital
- Campath (alemtuzumab) / Sanofi, Neupogen (filgrastim) / Kyowa Kirin, Amgen
New P2 trial: CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma (clinicaltrials.gov) - Mar 5, 2013
P2, N=41, Completed, Sponsor: University of G
- |||| plerixafor / Generic mfg.
Trial completion, Combination therapy: Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms (clinicaltrials.gov) - Mar 5, 2013
P4, N=61, Completed, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||| Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall
Enrollment open: reSURFACE 2: A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011) (clinicaltrials.gov) - Mar 4, 2013
P3, N=1050, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Enbrel (etanercept) / Pfizer, Amgen
Trial termination: ENBREL NIS CN: A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department (clinicaltrials.gov) - Mar 3, 2013
P4, N=166, Terminated, Sponsor: Pfizer
Not yet recruiting --> Recruiting Recruiting --> Terminated; See termination reason in detailed description.
- Actimmune (interferon gamma-1 b) / Clinigen, Amgen
Enrollment change: Cell Responses to IFN-gamma (clinicaltrials.gov) - Mar 3, 2013
P0, N=2, Terminated, Sponsor: Rockefeller University
Recruiting --> Terminated; See termination reason in detailed description. N=10 --> 2
- Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
Enrollment change: GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma (clinicaltrials.gov) - Mar 3, 2013
P2, N=14, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
N=10 --> 2 N=29 --> 14
- ivabradine / Generic mfg.
New P1 trial: Pharmacokinetic, Pharmacodynamic Profiles and Safety After Oral Administration of Ivabradine in Male Healthy Korean Volunteers (clinicaltrials.gov) - Mar 3, 2013
P1, N=48, Completed, Sponsor: Asan Medical Center
- ||||| Stivarga (regorafenib) / Bayer
Enrollment closed, Metastases: CONCUR: Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy (clinicaltrials.gov) - Mar 3, 2013
P3, N=204, Active, not recruiting, Sponsor: Bayer
N=29 --> 14 Recruiting --> Active, not recruiting
- Vectibix (panitumumab) / Amgen
Trial termination: VOXEL: Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer (clinicaltrials.gov) - Feb 28, 2013
P2, N=9, Terminated, Sponsor: AIO-Studien-gGmbH
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; Recruitment rate to low; changed environment made protocol in its current state obsolete
- azacitidine / Generic mfg., plerixafor / Generic mfg.
Trial initiation date, Combination therapy: Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Feb 28, 2013
P1, N=28, Recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Terminated; Recruitment rate to low; changed environment made protocol in its current state obsolete Initiation date: Apr 2010 --> Sep 2010
- plerixafor / Generic mfg.
Trial initiation date: Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 28, 2013
P1/2, N=39, Active, not recruiting, Sponsor: Washington University School of Medicine
Initiation date: Apr 2010 --> Sep 2010 Initiation date: Aug 2010 --> Feb 2011
- Vectibix (panitumumab) / Amgen
Enrollment change: VOXEL: Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer (clinicaltrials.gov) - Feb 28, 2013
P2, N=9, Terminated, Sponsor: AIO-Studien-gGmbH
Initiation date: Aug 2010 --> Feb 2011 N=174 --> 9
- Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
New P2 trial: PACER: A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 27, 2013
P2, N=41, Recruiting, Sponsor: National Cancer Institute, Naples
- | Ibrance (palbociclib) / Pfizer
New P1 trial: A Study Comparing the Plasma Drug Exposure of an Oral Dose of Palbociclib (PD-0332991) to an Intravenous Dose of Palbociclib (PD-0332991) (clinicaltrials.gov) - Feb 27, 2013
P1, N=14, Completed, Sponsor: Pfizer
- ||| Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Enrollment change: NCI-2011-01123: Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 26, 2013
P1/2, N=106, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=174 --> 9 N=66 --> 106
- topotecan / Generic mfg., melphalan / Generic mfg., busulfan / Generic mfg.
Enrollment closed: Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor (clinicaltrials.gov) - Feb 26, 2013
P=N/A, N=25, Active, not recruiting, Sponsor: City of Hope Medical Center
N=66 --> 106 Recruiting --> Active, not recruiting
- | Trial completion: SWOG 9438: Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 26, 2013
P3, N=206, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Prolia (denosumab) / Amgen, Daiichi Sankyo
New P2 trial: Translational Therapy in Patients With Osteogenesis Imperfecta - A Pilot Trial on Treatment With the Rankl-Antibody Denosumab (clinicaltrials.gov) - Feb 25, 2013
P2, N=10, Active, not recruiting, Sponsor: University of Cologne
- melphalan / Generic mfg., busulfan / Generic mfg., gemcitabine / Generic mfg.
Enrollment open: CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma (clinicaltrials.gov) - Feb 25, 2013
P2, N=24, Recruiting, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche
Enrollment closed: Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma (clinicaltrials.gov) - Feb 25, 2013
P1, N=25, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||||| Enbrel (etanercept) / Pfizer, Amgen
P3 data: A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis (clinicaltrials.gov) - Feb 25, 2013
P3, N=1108, Completed, Sponsor: Pfizer
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment change: Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors (clinicaltrials.gov) - Feb 21, 2013
P1/2, N=108, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed N=30 --> 108
- ||| navtemadlin (KRT-232) / Kartos Therap
Enrollment open, Metastases: A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma (clinicaltrials.gov) - Feb 20, 2013
P1, N=107, Recruiting, Sponsor: Amgen
N=30 --> 108 Not yet recruiting --> Recruiting
- ivabradine / Generic mfg.
New P4 trial: DIGvsIVA: Digoxin Versus Ivabradine in Heart Failure With Preserved Systolic Function (clinicaltrials.gov) - Feb 19, 2013
P4, N=42, Completed, Sponsor: Cocco, Giuseppe, M.D.
- |||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
New P3 trial: An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women (clinicaltrials.gov) - Feb 19, 2013
P3, N=400, Recruiting, Sponsor: Amgen